NO20012981L - Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme - Google Patents
Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av sammeInfo
- Publication number
- NO20012981L NO20012981L NO20012981A NO20012981A NO20012981L NO 20012981 L NO20012981 L NO 20012981L NO 20012981 A NO20012981 A NO 20012981A NO 20012981 A NO20012981 A NO 20012981A NO 20012981 L NO20012981 L NO 20012981L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- active ingredient
- biodegradable polymer
- solid solution
- useful
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000003420 antiserotonin agent Substances 0.000 title 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 239000006104 solid solution Substances 0.000 abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 229920002988 biodegradable polymer Polymers 0.000 abstract 1
- 239000004621 biodegradable polymer Substances 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 238000007580 dry-mixing Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- HXTGXYRHXAGCFP-UHFFFAOYSA-N volinanserin Chemical compound COC1=CC=CC(C(O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biological Depolymerization Polymers (AREA)
Abstract
En ny klasse bionedbrytbare farmasøytiske sammensetninger som er anvendelige som vedvarende frigivelses medikamentsamrnensetninger, som inkluderer fremgangsmåter for fremstilling og fremgangsmåter for anvendelse av disse sammensetningene, er beskrevet. Fremgangsmåten for fremstilling av disse sammensetningene inkluderer trinnene med å: a) tørrblande et farmasøytisk aktivt molekyl med en bionedbrytbar polymer; b) smelteekstrudere blandingen for å danne en fast løsning av det aktive molekylet i polymeren, og c) pulverisere den faste løsningen for å danne mikropartikler slik at de kan dannes til injiserbare formuleringer. Foretrukne utførelsesformer inkluderer farmasøytiske sammensetninger av polylaktid-ko-glykolid og (+)-a-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidinmetanol (aktiv ingrediens) og en fremgangsmåte for dens fremstilling. Disse sammensetningene frigir den aktive ingrediensen i en fast hastighet i løpet av dager til uker. Den aktive ingrediensen antagoniserer effektene av serotonin ved 5HT-reseptoren og er anvendelig ved behandling av forskjellige tilstander, slik som for eksempel psykoser som inkluderer schizofreni, obsessiv kompulsiv forstyrrelse, søvnforstyrrelser, depresjon, anoreksi, angst, legemiddelavhengighet og bipolare forstyrrelser.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21298698A | 1998-12-16 | 1998-12-16 | |
| PCT/US1999/027705 WO2000035423A1 (en) | 1998-12-16 | 1999-11-22 | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20012981D0 NO20012981D0 (no) | 2001-06-15 |
| NO20012981L true NO20012981L (no) | 2001-07-27 |
Family
ID=22793267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012981A NO20012981L (no) | 1998-12-16 | 2001-06-15 | Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1140026B1 (no) |
| JP (1) | JP4759141B2 (no) |
| KR (1) | KR100707710B1 (no) |
| CN (1) | CN1195497C (no) |
| AP (1) | AP1769A (no) |
| AR (1) | AR021652A1 (no) |
| AT (1) | ATE303795T1 (no) |
| AU (1) | AU770673B2 (no) |
| BG (1) | BG65500B1 (no) |
| BR (1) | BR9916276A (no) |
| CA (1) | CA2355077C (no) |
| CR (1) | CR6424A (no) |
| CZ (1) | CZ301947B6 (no) |
| DE (1) | DE69927177T2 (no) |
| DK (1) | DK1140026T3 (no) |
| EA (1) | EA004502B1 (no) |
| EE (1) | EE200100314A (no) |
| ES (1) | ES2245128T3 (no) |
| HK (1) | HK1041645B (no) |
| HR (1) | HRP20010446A2 (no) |
| HU (1) | HU226586B1 (no) |
| ID (1) | ID28909A (no) |
| IL (2) | IL143761A0 (no) |
| ME (2) | ME00066B (no) |
| NO (1) | NO20012981L (no) |
| NZ (1) | NZ511962A (no) |
| OA (1) | OA11728A (no) |
| PL (1) | PL196822B1 (no) |
| RS (1) | RS50123B (no) |
| SK (1) | SK285812B6 (no) |
| TR (1) | TR200101759T2 (no) |
| TW (1) | TWI221418B (no) |
| UA (1) | UA73101C2 (no) |
| WO (1) | WO2000035423A1 (no) |
| ZA (1) | ZA200104899B (no) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10061932A1 (de) * | 2000-12-13 | 2002-10-24 | Pharmatech Gmbh | Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion |
| AU2002256694A1 (en) * | 2001-03-20 | 2002-10-03 | Euroscreen S.A. | Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor |
| BR0209914A (pt) | 2001-05-23 | 2004-04-06 | Hexal Ag | Produto homogeneizado para implantes e micropartìculas |
| US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
| EP1797871B1 (en) * | 2004-09-21 | 2015-02-25 | Shandong Luye Pharmaceutical Co., Ltd. | Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
| EP2262484B1 (en) | 2008-03-11 | 2013-01-23 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| BRPI0913724B8 (pt) * | 2008-09-18 | 2021-05-25 | Purdue Pharma Lp | formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo |
| US20100291214A1 (en) * | 2008-12-23 | 2010-11-18 | Armark Authentication Technologies, Llc | Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure |
| WO2010151746A2 (en) * | 2009-06-26 | 2010-12-29 | Armark Authentication Technologies, Llc | Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure |
| US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
| US20160193151A1 (en) * | 2015-01-06 | 2016-07-07 | Maria Del Pilar Noriega Escobar | Dosage form incorporating an amorphous drug solid solution |
| BR112022012260A2 (pt) * | 2019-12-31 | 2022-08-30 | Wanka Tanka Ltd | Formulação plástica de liberação estendida |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| CH679207A5 (no) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| US5439688A (en) * | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
| EP0528978B1 (en) * | 1990-05-16 | 2002-10-16 | Southern Research Institute | Mikrocaspules for controlled release and their use to stimulate nerve fiber growth |
| DK0531410T3 (da) * | 1990-06-01 | 1995-01-30 | Merrell Dow Pharma | (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol |
| GB9016885D0 (en) * | 1990-08-01 | 1990-09-12 | Scras | Sustained release pharmaceutical compositions |
| KR0182801B1 (ko) * | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| US5505963A (en) * | 1993-04-07 | 1996-04-09 | Schwartz Pharma Ag | Slow release pharmaceutical preparation |
| US5456917A (en) * | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
| AU4467396A (en) * | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
-
1999
- 1999-11-22 JP JP2000587744A patent/JP4759141B2/ja not_active Expired - Fee Related
- 1999-11-22 SK SK828-2001A patent/SK285812B6/sk not_active IP Right Cessation
- 1999-11-22 ES ES99960556T patent/ES2245128T3/es not_active Expired - Lifetime
- 1999-11-22 DE DE69927177T patent/DE69927177T2/de not_active Expired - Lifetime
- 1999-11-22 AT AT99960556T patent/ATE303795T1/de active
- 1999-11-22 ID IDW00200101296A patent/ID28909A/id unknown
- 1999-11-22 CN CNB998145831A patent/CN1195497C/zh not_active Expired - Fee Related
- 1999-11-22 WO PCT/US1999/027705 patent/WO2000035423A1/en active IP Right Grant
- 1999-11-22 CA CA002355077A patent/CA2355077C/en not_active Expired - Fee Related
- 1999-11-22 AU AU17425/00A patent/AU770673B2/en not_active Ceased
- 1999-11-22 OA OA1200100150A patent/OA11728A/en unknown
- 1999-11-22 PL PL348233A patent/PL196822B1/pl not_active IP Right Cessation
- 1999-11-22 HU HU0105048A patent/HU226586B1/hu not_active IP Right Cessation
- 1999-11-22 UA UA2001064165A patent/UA73101C2/uk unknown
- 1999-11-22 EE EEP200100314A patent/EE200100314A/xx unknown
- 1999-11-22 DK DK99960556T patent/DK1140026T3/da active
- 1999-11-22 CZ CZ20012157A patent/CZ301947B6/cs not_active IP Right Cessation
- 1999-11-22 NZ NZ511962A patent/NZ511962A/xx not_active IP Right Cessation
- 1999-11-22 EA EA200100551A patent/EA004502B1/ru not_active IP Right Cessation
- 1999-11-22 RS YUP-414/01A patent/RS50123B/sr unknown
- 1999-11-22 KR KR1020017007561A patent/KR100707710B1/ko not_active IP Right Cessation
- 1999-11-22 TR TR2001/01759T patent/TR200101759T2/xx unknown
- 1999-11-22 EP EP99960556A patent/EP1140026B1/en not_active Expired - Lifetime
- 1999-11-22 AP APAP/P/2001/002198A patent/AP1769A/en active
- 1999-11-22 ME MEP-2008-194A patent/ME00066B/me unknown
- 1999-11-22 BR BR9916276-8A patent/BR9916276A/pt not_active Application Discontinuation
- 1999-11-22 IL IL14376199A patent/IL143761A0/xx active IP Right Grant
- 1999-11-22 ME MEP-194/08A patent/MEP19408A/xx unknown
- 1999-12-10 TW TW088121702A patent/TWI221418B/zh not_active IP Right Cessation
- 1999-12-14 AR ARP990106345A patent/AR021652A1/es unknown
-
2001
- 2001-06-12 BG BG105591A patent/BG65500B1/bg unknown
- 2001-06-14 HR HR20010446A patent/HRP20010446A2/hr not_active Application Discontinuation
- 2001-06-14 IL IL143761A patent/IL143761A/en not_active IP Right Cessation
- 2001-06-14 ZA ZA200104899A patent/ZA200104899B/en unknown
- 2001-06-15 NO NO20012981A patent/NO20012981L/no not_active Application Discontinuation
- 2001-07-16 CR CR6424A patent/CR6424A/es not_active Application Discontinuation
-
2002
- 2002-05-04 HK HK02103401.5A patent/HK1041645B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20012981L (no) | Bionedbrytbar polymerinnkapslet serotoninreseptorantagonist og fremgangsmate for fremstilling av samme | |
| JP5599115B2 (ja) | ２−オキソ−１−ピロリジン誘導体を含む医薬組成物 | |
| CA2474698A1 (en) | Polymer-based compositions for sustained release | |
| US20210212934A1 (en) | Methods for providing long-lasting anesthetic effect using microparticles | |
| CA2182593A1 (en) | Oral liquid compositions containing paroxetine resinate | |
| KR20080043852A (ko) | 신규 투여 제형 | |
| RU2003115490A (ru) | Амидные производные в качестве антагонистов nmda рецептора | |
| JP2004502729A (ja) | Ｓｓｒｉおよびエストロゲン剤の組み合わせ | |
| DE202006018608U1 (de) | Buprenorphin-Wafer zur Drogensubstitutionstherapie | |
| JPH062672B2 (ja) | パーキンソン疾患治療用薬剤 | |
| NZ592339A (en) | Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol | |
| US20020019392A1 (en) | Methods of treating neuropeptide Y-related conditions | |
| TW200835524A (en) | Solid dispersion composition | |
| EP0214058A2 (fr) | Composition pharmaceutique contenant des dérivés de l'histamine | |
| YU48766B (sh) | Postupak za dobijanje farmaceutskog preparata za oralnu primenu sa usporenim oslobađanjem aktivne supstance bez rastvarača | |
| JP2004502734A (ja) | 一酸化窒素シンターゼ活性の増強方法 | |
| JPH10508029A (ja) | 不安を治療する方法 | |
| EP2595607A2 (de) | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer | |
| WO2017003186A1 (en) | Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin | |
| JP2022548349A (ja) | 医薬製剤 | |
| CA2345406A1 (en) | Analgesic | |
| CA2253377A1 (fr) | Compositions pharmaceutiques pour la liberation prolongee de principes actifs insolubles | |
| US6369051B1 (en) | Combinations of SSRI and estrogenic agents | |
| YU64001A (sh) | Jedinjenja betahistina sa kontrolisanim oslobadjanjem | |
| CN1243540C (zh) | 用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |